Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Bavarian Nordic Stories

2013-12-06 04:20:49

LONDON, Dec. 6, 2013 /PRNewswire/ -- Edison Investment Research's report, An intriguing PROSPECT, examines the long-term investment case for Bavarian Nordic, which rests on key value driver Prostvac, its Phase III prostate cancer vaccine. Prostvac is well positioned to succeed where Provenge, the only approved prostate cancer vaccine, has so far failed. Final data from the pivotal Phase III PROSPECT trial are not due until 2016 but with enrolment on track to complete in H114, there...

2013-07-01 12:27:28

Leadership Team Will Advance Industry Efforts Supporting the Development of Medical Countermeasures Against National Security Threats WASHINGTON, July 1, 2013 /PRNewswire/ -- The Alliance for Biosecurity announced it recently elected Anders Hedegaard, President and CEO, Bavarian Nordic, and Elizabeth Posillico, PhD, President and CEO, Elusys Therapeutics, as its new co-chairs. They will represent the Alliance before the U.S. government and other agencies, to advance the development...

2008-11-06 11:17:54

Bavarian Nordic, an industrial biotechnology company, has completed a clinical safety report from a large Phase II study with Imvamune in HIV infected subjects that confirms the excellent safety profile of Imvamune. Within the next few days the safety report of this study will be submitted to the FDA and this will trigger a $25 million milestone payment under the RFP-3 contract. The clinical safety report constitutes a major part of the data package that will be used to potentially support...

2008-10-07 09:00:56

Bavarian Nordic, an industrial biotechnology company, has evaluated the mature Phase II data from the therapeutic prostate cancer vaccine candidate Prostvac that had been obtained as part of the recently entered partnership with the National Cancer Institute in the US. The results from the Phase II prospective randomized placebo-controlled study of 125 patients with advanced prostate cancer after four years of follow-up show that patients receiving Prostvac had a statistically significantly...

2008-08-15 09:01:04

Bavarian Nordic's US subsidiary, BN ImmunoTherapeutics, has entered into a scientific partnership with the National Cancer Institute in the US. Under the co-operative R&D agreement, both the entities will jointly develop new immunotherapies for the treatment of prostate cancer. Under the co-operative R&D agreement, BN ImmunoTherapeutics has rights to exclusively license intellectual property that results from this collaboration. Bavarian Nordic will in the future explore...